Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain

[1]  J. Starrfelt,et al.  Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[2]  R. Blasczyk,et al.  Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  C. Rice,et al.  Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection , 2021, Nature.

[4]  P. Muñoz,et al.  First importations of SARS-CoV-2 P.1 and P.2 variants from Brazil to Spain and early community transmission , 2021, Enfermedades infecciosas y microbiologia clinica.

[5]  B. Ramos,et al.  The Demography and Characteristic of SARS-CoV-2 Sero-positive Residents and Staff of Nursing Homes for Older Adults in the Community of Madrid: the SeroSOS Study , 2021, Age and ageing.

[6]  A. M. Fernández Alonso,et al.  Pregnancy Outcomes and SARS-CoV-2 Infection: The Spanish Obstetric Emergency Group Study , 2021, Viruses.

[7]  V. Soriano,et al.  Third wave of COVID-19 in Madrid, Spain , 2021, International Journal of Infectious Diseases.

[8]  V. Cuervas-Mons,et al.  Major determinants of death in patients hospitalized with COVID-19 during the first epidemic wave in Madrid, Spain , 2021, Medicine.

[9]  R. Darnell,et al.  Vaccine Breakthrough Infections with SARS-CoV-2 Variants , 2021, The New England journal of medicine.

[10]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[11]  A. Huppert,et al.  Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals , 2021, Nature Medicine.

[12]  J. M. Lorenzo-Salazar,et al.  Monitoring the rise of the SARS-CoV-2 lineage B.1.1.7 in Tenerife (Spain) since mid-December 2020 , 2021, Journal of Infection.

[13]  V. Soriano,et al.  Main differences between the first and second waves of COVID-19 in Madrid, Spain , 2021, International Journal of Infectious Diseases.

[14]  Q. Bi,et al.  SARS-CoV-2 setting-specific transmission rates: a systematic review and meta-analysis. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  A. Fauci,et al.  SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn , 2021, Annals of Internal Medicine.

[16]  H. Schuitemaker,et al.  Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine , 2021, The New England journal of medicine.

[17]  R. G. Crespo,et al.  A new SEAIRD pandemic prediction model with clinical and epidemiological data analysis on COVID-19 outbreak , 2021, Appl. Intell..

[18]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[19]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[20]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[21]  A. Fauci,et al.  Emerging Pandemic Diseases: How We Got to COVID-19 , 2020, Cell.

[22]  K. Walker.  SARS-CoV-2 Vaccine , 2020, Global reproductive health.

[23]  A. Fauci,et al.  Emerging Pandemic Diseases: How We Got to COVID-19 , 2020, Cell.

[24]  M. Hernán,et al.  Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.

[25]  V. Soriano,et al.  Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity , 2020, International Journal of Infectious Diseases.

[26]  V. Soriano,et al.  Why such excess of mortality for COVID-19 in Spain? , 2020, Therapeutic advances in infectious disease.

[27]  Muhammad Dur-e-Ahmad,et al.  Transmission Dynamics Model of Coronavirus COVID-19 for the Outbreak in Most Affected Countries of the World , 2020, Int. J. Interact. Multim. Artif. Intell..